 |
인쇄하기
취소
|
Handok-Aventis Introduces Once-Daily Basal Insulin Treatment
Handok-Aventis Pharma announced that the company is to launch Lantus (insulin glargine [rDNA origin] injection) for the treatment of type 1 and type 2 diabetes in the domestic market starting March 29th.
Lantus is indicated for once-daily subcutaneous administration for the treatment of adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hy...
Lantus is indicated for once-daily subcutaneous administration for the treatment of adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hy...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.